Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | ATF1 | P18846 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30068217 | 0.84 | ALDH1A1 (0.38) | SYKSTK17BSTK17AALKAAK1 | |
| SCHEMBL26647074 | 0.84 | ALDH1A1 (0.38) | SYKSTK17BSTK17AALKAAK1 | |
| SCHEMBL30550836 | 0.80 | STK17B (0.45) | SYKSTK17BSTK17AAAK1PDPK1 | |
| SCHEMBL25323395 | 0.80 | STK17B (0.45) | SYKSTK17BSTK17AAAK1PDPK1 | |
| SCHEMBL26975222 | 0.79 | SYK (0.40) | SYKSTK17BSTK17AAAK1PDPK1 | |
| SCHEMBL13199706 | 0.75 | AAK1 (0.39) | ALKAAK1PDPK1USP30 | |
| SCHEMBL29651923 | 0.75 | AAK1 (0.39) | ALKAAK1PDPK1USP30 | |
| SCHEMBL28718726 | 0.74 | ALKBH1 (0.35) | SYKPDPK1USP30 | |
| SCHEMBL18786760 | 0.73 | PDPK1 (0.38) | PDPK1USP30 | |
| SCHEMBL30990212 | 0.73 | ALK (0.34) | ALKAAK1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | SYK 2284/4885STK17B 89/4885STK17A 35/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | SYK 2284/4885STK17B 89/4885STK17A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.